Introduction
Jevtana IV Infusion 60 mg/1.5 ml is a chemotherapy drug used primarily in the treatment of prostate cancer. It is a taxane derivative that functions by inhibiting cell division. Jevtana IV Infusion 60 mg/1.5 ml is often used in cases where the cancer has become resistant to other treatments, particularly after the failure of docetaxel-based therapies.
Uses
Jevtana IV Infusion 60 mg/1.5 ml is used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) after the failure of docetaxel-based chemotherapy. It is often administered in combination with prednisone to enhance its efficacy. Jevtana IV Infusion 60 mg/1.5 ml is also being investigated for its potential use in other types of cancer, though its primary indication is prostate cancer.
| Brand Name | Jevtana |
|---|---|
| Type | IV Infusion |
| Weight | 60 mg/1.5 ml |
| Generic | Cabazitaxel |
| Manufacturer | Sanofi Bangladesh Ltd. (Mfg. by: Genzyme Corporation) |
| Available in | English বাংলা |
Mechanism of Action
Jevtana IV Infusion 60 mg/1.5 ml works by stabilizing microtubules and preventing their depolymerization. This action inhibits the mitotic spindle formation during cell division, which leads to cell cycle arrest and ultimately induces apoptosis. The stabilization of microtubules interferes with the normal function of the mitotic spindle, disrupting the normal process of cell division.
How Long Does It Take to Work?
The clinical response to cabazitaxel treatment can vary, but patients may start to see improvements in symptoms or disease markers within a few weeks of initiating therapy. Full assessment of the drug’s efficacy generally occurs after a few cycles of treatment, as cancer response can be gradual and may require time to become evident.
Absorption
Jevtana IV Infusion 60 mg/1.5 ml is administered intravenously, so absorption into the bloodstream is not a factor. The drug is directly delivered into the systemic circulation through intravenous infusion.
Route of Elimination
Jevtana IV Infusion 60 mg/1.5 ml is primarily metabolized in the liver by the cytochrome P450 enzyme system, particularly CYP3A4. The drug and its metabolites are excreted mainly in the feces. A smaller portion is eliminated through the urine.
Dosage
25 mg/m2 administered as a 1 hr IV infusion every 3 wk in combination with oral prednisone or prednisolone 10 mg administered daily throughout treatment.The typical dosage of cabazitaxel for treating metastatic castration-resistant prostate cancer is 25 mg/m² administered intravenously every 3 weeks. The dose may be adjusted based on patient tolerance and specific clinical circumstances, including potential side effects and blood counts.
Administration
Jevtana IV Infusion 60 mg/1.5 ml is administered via intravenous infusion over a period of approximately 1 hour. It is usually given in a healthcare setting where medical professionals can monitor the patient for any immediate reactions or side effects. The infusion is typically administered every 3 weeks.
Side Effects
Common side effects of cabazitaxel include neutropenia (low white blood cell count), anemia, fatigue, nausea, vomiting, diarrhea, and alopecia (hair loss). Other potential side effects may include febrile neutropenia (fever with low white blood cells), peripheral neuropathy, and gastrointestinal issues.
Toxicity
Toxicity associated with cabazitaxel includes myelosuppression, leading to an increased risk of infections and bleeding due to low blood cell counts. Liver toxicity, manifested as elevated liver enzymes, and gastrointestinal toxicity are also notable concerns. Regular monitoring and supportive care are necessary to manage and mitigate these toxic effects.
Precautions
Precautions should be taken in patients with pre-existing liver impairment or those receiving concurrent treatments that may affect liver function. Patients with a history of severe allergic reactions to taxanes should be monitored closely. The drug should be administered under the supervision of a healthcare provider experienced in the use of antineoplastic agents.
Interaction
Jevtana IV Infusion 60 mg/1.5 ml is metabolized by CYP3A4, so drugs that inhibit or induce this enzyme may affect its levels. Careful monitoring is required when used with other medications that impact CYP3A4 activity, such as certain antifungals, antibiotics, and antiepileptics.
Disease Interaction
Patients with liver impairment, renal impairment, or bone marrow suppression should use cabazitaxel with caution. The drug may exacerbate these conditions or increase the risk of severe side effects, requiring dose adjustments and careful monitoring.
Drug Interaction
Jevtana IV Infusion 60 mg/1.5 ml may interact with other drugs that affect the cytochrome P450 system, particularly CYP3A4. This includes both inhibitors (e.g., ketoconazole) and inducers (e.g., rifampicin). Interaction with other chemotherapeutic agents should also be considered to avoid overlapping toxicities.
Food Interactions
As cabazitaxel is administered intravenously, there are no direct food interactions. However, general dietary recommendations should be followed to maintain overall health and support the body's response to treatment.
Pregnancy Use
Jevtana IV Infusion 60 mg/1.5 ml is classified as Category D during pregnancy, indicating that there is evidence of risk to the fetus. The drug should be avoided during pregnancy unless the benefits outweigh the risks. Adequate contraception is recommended for women of childbearing potential undergoing treatment.
Lactation Use
It is unknown whether cabazitaxel is excreted in breast milk, but due to potential risks, breastfeeding is generally not recommended during treatment. Patients should discuss alternative feeding options with their healthcare provider.
Acute Overdose
Acute overdose of cabazitaxel can result in severe myelosuppression, leading to increased risk of infections, bleeding, and anemia. In case of overdose, supportive care and symptomatic treatment are required. Immediate medical attention is necessary.
Contraindication
Jevtana IV Infusion 60 mg/1.5 ml is contraindicated in patients with hypersensitivity to cabazitaxel or other taxanes, severe liver impairment, and in those who are pregnant. It should also be avoided in patients with neutrophil counts below acceptable levels or those with uncontrolled infections.
Use Direction
Patients should follow the prescribed dosage and schedule for cabazitaxel exactly as directed. Regular monitoring of blood counts and liver function is essential. Any signs of adverse effects should be reported to a healthcare provider promptly.
Storage Conditions
Jevtana IV Infusion 60 mg/1.5 ml should be stored in its original vial at room temperature, protected from light. It should not be frozen or shaken. Any unused or expired medication should be disposed of according to local regulations.
Volume of Distribution
The volume of distribution of cabazitaxel is approximately 80 L, indicating its extensive distribution into body tissues.
Half Life
The half-life of cabazitaxel is approximately 40 to 50 hours. This prolonged half-life allows for less frequent dosing schedules, typically every 3 weeks.
Clearance
Jevtana IV Infusion 60 mg/1.5 ml clearance is primarily hepatic, with about 20% of the drug excreted unchanged in the urine. Clearance can be affected by liver function and other factors, necessitating dose adjustments in certain patient populations.
See in details version Jevtana IV Infusion 60 mg/1.5 ml also Jevtana IV Infusion 60 mg/1.5 ml in bangla
